Eli Lilly and Company reported positive results from two late-stage ATTAIN-OSA trials evaluating its once-daily oral GLP-1 drug Foundayo, also known as orforglipron, in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight. The 52-week studies met their primary endpoint by reducing the apnea-hypopnea index, the standard measure of sleep-apnea severity. Among 363 participants not using positive airway pressure (PAP) therapy, Foundayo reduced breathing interruptions by 21.1 events per hour, or 43.8%, from a baseline of 50.7, compared with 4.3 events per hour for placebo. Among 349 PAP users, the reduction was 18.3 events per hour, or 27.5%, from a baseline of 57.6. Lilly’s rounded headline description cited reductions of up to 44%. Foundayo also improved sleep apnea-specific hypoxic burden, body weight and systolic blood pressure, although gastrointestinal side effects were the most common adverse events and treatment discontinuations were higher than with placebo. Lilly plans to submit the results to the U.S. Food and Drug Administration by the end of 2026. Lilly shares rose 2.35% to $1,385.56 in premarket trading on Monday and were later reported up 3.26% during the session. Jefferies raised its price target from $1,610 to $1,700, the highest on Wall Street, saying the potential patient pool outside the United States could be about twice the size of the American market. The brokerage cited higher realized prices at increased doses, stronger international margins, the economics of oral medicines and Lilly’s broader obesity-treatment portfolio. It also argued that patients increasingly choose GLP-1 drugs based on efficacy, tolerability, convenience and price rather than treating them as interchangeable commodities, while noting that adoption abroad may take longer than in the United States.